RTTNews | Dec 16, 2021 06:49AM EST

06:48 Thursday, December 16, 2021 (RTTNews.com) - SAB Biotherapeutics (SABS), said on Thursday that its therapeutic candidate -SAB-185 for the treatment of Covid-19 infections, retained neutralization impact against the Omicron SARS-CoV-2 variant in an in vitro pseudovirus model.

The data on SAB's SAB-185 was generated by the experts at the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER).

The additional analyses on SAB-185 are being completed, and the full data is expected to be sent to bioRxiv, the online life sciences archive for Covid-19 SARS-CoV-2 preprints.

SAB-185 is currently being assessed in a Phase 3 trial that has been enrolling patients since October.

The antibodies within SAB-185 are directed against multiple epitopes within the full-length spike protein of the SARS-CoV-2 Wuhan strain.

SAB-185 neutralizes the Munich, South African, Delta, Lambda, and other circulating variant strains in nonclinical studies, the company said in a statement.

Read the original article on RTTNews ( https://www.rttnews.com/3249844/sab-says-in-vitro-data-showed-sab-185-retains-neutralization-impact-to-fight-omicron-variant.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved